BioWorld

July 19, 2007

View Archived Issues

Neurochem Gets 2nd Approvable For Kiacta; Analysts Pessimistic

Almost a year after Neurochem Inc. received its first approvable letter for Kiacta (eprodisate) in the treatment of AA amyloidosis, history repeated itself. (BioWorld Today) Read More

Preparing For AzaSite Launch, Inspire Gets $75M Investment

Read More

Edison, Penwest Enter Deal On Orphan Neurological Disorders

Read More

Clinical Data Boost Vilazodone Work With $66M Public Offering

Read More

Orchestra Dumps HIV Program After Vaccine Candidate Fails

Read More

Appointments And Advancements

Read More

Other News To Note

Read More

Clinic Roundup

Read More